Aripiprazole (1,1,2,2,3,3,4,4-d8)

Aripiprazole (1,1,2,2,3,3,4,4-d8)

• CAS Number: 1089115-04-7
• UNSPSC Description: Aripiprazole (1,1,2,2,3,3,4,4-d8) is the deuterium labeled Aripiprazole. Aripiprazole (OPC-14597) is a human 5-HT1A receptor partial agonist with a Ki of 4.2 nM[1][2].
• Target Antigen: 5-HT Receptor; Isotope-Labeled Compounds
• Type: Isotope-Labeled Compounds
• Related Pathways: GPCR/G Protein;Neuronal Signaling;Others
• Field of Research: Neurological Disease
• Solubility: 10 mM in DMSO
• Smiles: O=C1NC2=C(C=CC(OC([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])N3CCN(C4=CC=CC(Cl)=C4Cl)CC3)=C2)CC1
• Molecular Weight: 456.43
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Stip E, Tourjman V. et al. Aripiprazole in schizophrenia and schizoaffective disorder: A review. Clin Ther. 2010;32 Suppl 1:S3-20.|[3]Burris KD, Molski TF, Xu C et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002 Jul;302(1):381-9.|[4]Swainston Harrison T, Perry CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. 2004;64(15):1715-36.|[5]Nagasaka Y, Oda K, Iwatsubo T, Kawamura A, Usui T.
 Nagasaka Y, Oda K, Iwatsubo T, Kawamura A, Usui T.
 Effects of aripiprazole and its active metabolite dehydroaripiprazole on the activities of drug efflux transporters expressed both in the intestine and at the blood-brain barrier.
 Biopharm Drug Dispos. 2012 Jul 27. doi: 10.1002/bdd.1801.
• Shipping Conditions: Room Temperature
• Clinical Information: Launched